

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  26D0440645	<b>(X3) Date Survey Completed</b>  09/05/2023
<b>Name of Provider or Supplier</b>  Arthritis Consultants, Inc	<b>Street Address, City, State</b>  522 N New Ballas, Suite 240, Saint Louis, MO	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D2016</b>	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on review of 2022 and 2023 hematology proficiency testing (PT) results reported to the CLIA database by the PT provider and phone interview with the laboratory director, the laboratory failed to successfully participate in PT. See D-tag 2130; unsuccessful performance in two out of three consecutive red blood cell count PT events.</p>
<b>D2130</b>	<p>HEMATOLOGY CFR(s): 493.851(f)</p>

Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on review of hematology proficiency testing (PT) records for 2022/2023 and phone interview with the laboratory director, the laboratory failed to achieve satisfactory performance for red blood cell count in two out of three consecutive PT events. Findings: 1. Review of hematology PT results for the third event of 2022 showed the laboratory obtained an unacceptable score of 60 percent for red blood cell count. 2. Review of hematology PT results for the second event of 2023 showed the laboratory obtained an unacceptable score of 60 percent for red blood cell count. 3. Phone interview with the laboratory director on August 31, 2023 at 11:00 AM confirmed the laboratory failed to achieve satisfactory performance for red blood cell count in two out of three consecutive PT events.